Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.

Vogelmeier CF, Kostikas K, Fang J, Tian H, Jones B, Morgan CL, Fogel R, Gutzwiller FS, Cao H.

Respir Res. 2019 Aug 7;20(1):178. doi: 10.1186/s12931-019-1130-y.

2.

Personalized medicine for patients with COPD: where are we?

Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, Maxheim M, Roessler FK, Spruit MA, Vogelmeier CF, Wouters EF, Schmeck B.

Int J Chron Obstruct Pulmon Dis. 2019 Jul 9;14:1465-1484. doi: 10.2147/COPD.S175706. eCollection 2019.

3.

It is time for the world to take COPD seriously: a statement from the GOLD board of directors.

Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, Aisanov Z, Obaseki D, Decker R, Agusti A.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900914. doi: 10.1183/13993003.00914-2019. Print 2019 Jul. No abstract available.

PMID:
31273036
4.

Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort.

Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fähndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jörres RA, Bals R; COSYCONET consortium.

Respir Med. 2019 Jul - Aug;154:18-26. doi: 10.1016/j.rmed.2019.06.007. Epub 2019 Jun 11.

PMID:
31203096
5.

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.

Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019.

6.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA and TERRANOVA Study Investigators.

N Engl J Med. 2019 May 20. doi: 10.1056/NEJMoa1905248. [Epub ahead of print]

PMID:
31112385
7.

["Digitalization in Internal Medicine" - not "Digitalization of Internal Medicine" - a Promising Perspective from Non-Digital Natives].

Vogelmeier CF, Köhler F.

Dtsch Med Wochenschr. 2019 Apr;144(7):425. doi: 10.1055/a-0746-5964. Epub 2019 Mar 29. German. No abstract available.

PMID:
30925594
8.

[Digital medicine].

Hasenfuß G, Vogelmeier CF.

Internist (Berl). 2019 Apr;60(4):317-318. doi: 10.1007/s00108-019-0594-7. German. No abstract available.

PMID:
30923862
9.

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD.

Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.

10.

[Orphan drugs].

Schäfer JR, Vogelmeier CF.

Internist (Berl). 2019 Apr;60(4):396-398. doi: 10.1007/s00108-019-0582-y. German. No abstract available.

PMID:
30859277
11.

Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study.

Kostikas K, Greulich T, Mackay AJ, Lossi NS, Aalamian-Mattheis M, Nunez X, Pagano VA, Patalano F, Clemens A, Vogelmeier CF.

ERJ Open Res. 2019 Feb 25;5(1). pii: 00243-2018. doi: 10.1183/23120541.00243-2018. eCollection 2019 Feb.

12.

Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests.

Topalovic M, Das N, Burgel PR, Daenen M, Derom E, Haenebalcke C, Janssen R, Kerstjens HAM, Liistro G, Louis R, Ninane V, Pison C, Schlesser M, Vercauter P, Vogelmeier CF, Wouters E, Wynants J, Janssens W; Pulmonary Function Study Investigators; Pulmonary Function Study Investigators:.

Eur Respir J. 2019 Apr 11;53(4). pii: 1801660. doi: 10.1183/13993003.01660-2018. Print 2019 Apr.

PMID:
30765505
13.

Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.

von Siemens SM, Jörres RA, Behr J, Alter P, Lutter J, Lucke T, Söhler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group.

Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.

14.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
15.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

16.

Medical Treatment of COPD.

Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH.

Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.

17.

Proviral MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of Patients With Influenza Virus-Induced Acute Respiratory Distress Syndrome.

Scheller N, Herold S, Kellner R, Bertrams W, Jung AL, Janga H, Greulich T, Schulte LN, Vogelmeier CF, Lohmeyer J, Schmeck B.

J Infect Dis. 2019 Jan 29;219(4):540-543. doi: 10.1093/infdis/jiy554.

PMID:
30239899
18.

Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.

Buhl R, Criée CP, Kardos P, Vogelmeier CF, Kostikas K, Lossi NS, Worth H.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 24;13:2557-2568. doi: 10.2147/COPD.S169958. eCollection 2018.

19.

Influence of body mass on predicted values of static hyperinflation in COPD.

Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.

20.

COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study.

Klasan A, Dworschak P, Heyse TJ, Ruchholtz S, Alter P, Vogelmeier CF, Schwarz P.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 21;13:2495-2499. doi: 10.2147/COPD.S161577. eCollection 2018.

21.

Real world evaluation of a novel lateral flow assay (AlphaKit® QuickScreen) for the detection of alpha-1-antitrypsin deficiency.

Greulich T, Rodríguez-Frias F, Belmonte I, Klemmer A, Vogelmeier CF, Miravitlles M.

Respir Res. 2018 Aug 13;19(1):151. doi: 10.1186/s12931-018-0826-8.

22.

[Antibiotics: The Most Important Discovery in Medicine of the 20th Century].

Vogelmeier CF.

Dtsch Med Wochenschr. 2018 Aug;143(15):1057. doi: 10.1055/a-0606-1729. Epub 2018 Jul 30. German. No abstract available.

PMID:
30060272
23.

Design and application of an MR reference phantom for multicentre lung imaging trials.

Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jörres RA, Kauczor HU, Heußel CP, Wielpütz MO, Jobst BJ.

PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.

24.

Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach.

Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jörres RA.

Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.

25.

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA.

Kardos P, Mokros I, Sauer R, Vogelmeier CF.

Int J Chron Obstruct Pulmon Dis. 2018 May 3;13:1455-1468. doi: 10.2147/COPD.S159827. eCollection 2018.

26.

Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jörres RA.

Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.

27.

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

28.

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.

29.

Left ventricular volume and wall stress are linked to lung function impairment in COPD.

Alter P, Jörres RA, Watz H, Welte T, Gläser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF.

Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.

PMID:
29657040
30.

Blood eosinophils as a marker of eosinophilic exacerbations in COPD.

Greulich T, Vogelmeier CF.

Lancet Respir Med. 2018 May;6(5):e17. doi: 10.1016/S2213-2600(18)30095-X. Epub 2018 Apr 5. No abstract available.

PMID:
29627195
31.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

32.

Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling.

Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.

PMID:
29605197
33.

Exacerbations of COPD.

Viniol C, Vogelmeier CF.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170103. doi: 10.1183/16000617.0103-2017. Print 2018 Mar 31. Review.

34.

The revised GOLD 2017 COPD categorization in relation to comorbidities.

Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.

35.

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, Blasi F, Vogelmeier CF.

Respir Res. 2018 Jan 18;19(1):11. doi: 10.1186/s12931-018-0715-1. Review.

36.

The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort.

Wacker ME, Kitzing K, Jörres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R.

Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.

37.

Prevalence of comorbidities in COPD patients by disease severity in a German population.

Greulich T, Weist BJD, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, Alter P, Vogelmeier CF.

Respir Med. 2017 Nov;132:132-138. doi: 10.1016/j.rmed.2017.10.007. Epub 2017 Oct 12.

PMID:
29229085
38.

Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):968-969. doi: 10.1164/rccm.201710-2027LE. No abstract available.

PMID:
29140725
39.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
40.

GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.

Worth H, Buhl R, Criée CP, Kardos P, Lossi NS, Vogelmeier CF.

Respir Med. 2017 Oct;131:77-84. doi: 10.1016/j.rmed.2017.08.008. Epub 2017 Aug 9.

41.

Cardiovascular risk in patients with alpha-1-antitrypsin deficiency.

Fähndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jörres RA, Greulich T, Vogelmeier CF, Bals R; COSYCONET investigators.

Respir Res. 2017 Sep 15;18(1):171. doi: 10.1186/s12931-017-0655-1.

42.

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.

43.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

44.

Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1230-1231. doi: 10.1164/rccm.201706-1105LE. No abstract available.

45.

[Orphan diseases - on the way to better patient care].

Vogelmeier CF.

Dtsch Med Wochenschr. 2017 Jun;142(11):777-778. doi: 10.1055/s-0043-100842. Epub 2017 May 31. German. No abstract available.

PMID:
28564726
46.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

47.

Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study.

Boeselt T, Nell C, Lütteken L, Kehr K, Koepke J, Apelt S, Veith M, Beutel B, Spielmanns M, Greulich T, Vogelmeier CF, Kenn K, Janciauskiene S, Alter P, Koczulla AR.

Respiration. 2017;93(5):301-310. doi: 10.1159/000464139. Epub 2017 Mar 23.

48.

Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA.

Am J Respir Crit Care Med. 2017 May 1;195(9):1189-1197. doi: 10.1164/rccm.201701-0193OC.

49.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

50.

Myocardial homing of mesenchymal stem cells following intrapericardial application and amplification by inflammation - an experimental pilot study.

Jung N, Rupp H, Koczulla AR, Vogelmeier CF, Alter P.

Can J Physiol Pharmacol. 2017 Sep;95(9):1064-1066. doi: 10.1139/cjpp-2016-0373. Epub 2017 Feb 23.

Supplemental Content

Loading ...
Support Center